நான்காவது காலாண்டு அறிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நான்காவது காலாண்டு அறிக்கை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நான்காவது காலாண்டு அறிக்கை Today - Breaking & Trending Today

Maha Energy AB Announce Filing of Fourth Quarter Report 2020 & Live Webcast


Revenue of USD 8.7 million (Q4 2019: USD 13.7 million)
Operating netback of USD 4.2 million or USD 17.66 per BOE (Q4 2019: USD 9.8 million or USD 35.00 per BOE)
EBITDA of USD 2.7 million (Q4 2019: USD 8.4 million)
Net result of USD -15.7 million, following the previously announced impairment charge of 21.0 million for LAK Ranch (Q4 2019: USD 2.7 million)
Basic earnings per share of USD -0.15 (Q4 2019: USD 0.03)
Diluted earnings per share of USD -0.15 (Q4 2019: USD 0.02)
The Company was awarded new exploration block 70 (Mafraq) onshore Oman
Drilled and completed the Tie-2 well in the Tie Field and spudded the Tie-3 well on 18 December 2020
2P Reserve Replacement Ratio for 2020: 380% (Q4 2019: 147%) ....

United States , Bagua Grande , Jonas Lindvall , Kaarlo Airaxin , Andres Modarelli , Maha Energy , Shareholders Of Maha Energy , Fourth Quarter Report , Reserve Replacement Ratio , Nasdaq Stockholm , Daily Production , Fellow Shareholders , During January , Illinois Basin , Direkts Youtube Channel , Investor Relations , Stockholm Stock Exchange Maha A , Maha Energy Ab , ஒன்றுபட்டது மாநிலங்களில் , மஹா ஆற்றல் , பங்குதாரர்கள் ஆஃப் மஹா ஆற்றல் , நான்காவது காலாண்டு அறிக்கை , இருப்பு மாற்று ரேஶியோ , நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் , தினசரி ப்ரொடக்ஶந் , சக பங்குதாரர்கள் ,

Arcutis Biotherapeutics Reports Operational Progress, Financial Loss in Fourth Quarter | San Fernando Valley Business Journal


Arcutis Biotherapeutics reported robust business progress in conjunction with its fourth-quarter earnings report on Wednesday, including 18 clinical trials for three different product candidates in the dermatology market.
The Westlake Village biopharmaceutical company, which completed its IPO in January last year, reported a net loss of $34 million (-79 cents per share) for the quarter ended Dec. 31, compared to a net loss of $12.6 million (-$6.13 per share) for the corresponding period last year.
Analysts on average expected a net loss of $38 million (-88 cents per share) for the fourth quarter, according to Yahoo Finance.
Net loss for the year was $136 million (-$3.80 per share) compared to $42 million (-$22.78 per share) in 2019. ....

Arcutis Biotherapeutics , Frank Watanabe , Amy Stulick , Financial Loss , Westlake Village , Nasdaq Biotechnology , New Drug , Fourth Quarter Report , வெளிப்படையான வாடேநாப்ய் , நிதி இழப்பு , வெஸ்ட்லேக் கிராமம் , நாஸ்டாக் உயிரி தொழில்நுட்பவியல் , புதியது மருந்து , நான்காவது காலாண்டு அறிக்கை ,